Denmark-based Genmab A/S’ (GMXAY.OB) Arzerra, which won its first FDA approval in October 2009 for Chronic Lymphocytic Leukemia, is at the altar again awaiting a decision.The company’s supplemental Biologics License Application for the use of Arzerra in combination with Fludarabine and Cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia is now under priority review – with a decision date set for September 10, 2016.Arzerra is marketed under a collaboration agreement between Genmab and Novartis.Net sales of Arzerra by Novartis and GSK for the full year 2015 were GBP 37.3 million, which resulted in royalty income of DKK 76 million to Genmab.The product is also being explored as a potential treatment for relapsing multiple sclerosis.Novartis will start enrolling patients with relapsing multiple sclerosis in phase III studies of Arzerra in September 2016.